Home Page
About us
- Overview
- Organization
Technology
- Abiprot^TM-antibody platform
- Abiprot Select^TM
Portfolio
Corporate Governance
Investors Relations
- Financial Reports
  - Annual Reports for the years 2016-2019
News
- Press Releases
- Publications, conferences & press
Contact

Oblique Therapeutics > News > 2019 > November

Home Page
About us
- Overview
- Organization
Technology
- Abiprot^TM-antibody platform
- Abiprot Select^TM
Portfolio
Corporate Governance
Investors Relations
- Financial Reports
  - Annual Reports for the years 2016-2019
News
- Press Releases
- Publications, conferences & press
Contact

News

Archive

June 2021
April 2021
March 2021
November 2020
October 2020
September 2020
June 2020
November 2019
October 2019
July 2019
March 2019
January 2019

Categories

Company updates
News

27 Nov 2019

Notice convening the Extraordinary General Meeting on December 6 at 2pm

Copyright © 2021 Oblique Therapeutics AB.

Contact

Oblique Therapeutics AB
info@obliquet.com

Gothenburg
Arvid Wallgrens Backe 20
413 46 Göteborg
Sweden

Stockholm
Döbelnsgatan 64
113 52 Stockholm
Sweden

Menu

Home Page
About us
- Overview
- Organization
Technology
- Abiprot^TM-antibody platform
- Abiprot Select^TM
Portfolio
Corporate Governance
Investors Relations
- Financial Reports
  - Annual Reports for the years 2016-2019
News
- Press Releases
- Publications, conferences & press
Contact

About

Oblique Therapeutics is a privately held Swedish biotech developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain, and advanced cancer. The company uses AbiprotTM, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome.